The primary objective of this study is to assess the efficacy of rifaximin SSD-40IR versus placebo to delay the occurrence of hepatic encephalopathy (HE)-related hospitalization.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
A Barritt
Center for Gastrointestinal Biology and Disease
Clinical or Medical
Interventional
Kidneys and Liver
23-1481
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
